Abstract
Purpose
In a low-risk gestational trophoblastic neoplasia (GTN) treated with methotrexate (MTX), the modeled hCG (human chorionic gonadotropin) residual concentration (hCGres), calculated with NONMEM program® (NM) during the first 50 treatment days, is a predictor of MTX-resistance risk. This model was implemented with another algorithm on https://www.biomarker-kinetics.org/hCG. The objective was to confirm the validity of the website estimations with respect to NM.
Methods
The consistencies of modeled hCGres estimated by NM and by the website were assessed in a dataset of 60 fictive patients with simulated hCG profiles, as well as in an independent database of 531 actual patients. Moreover, the hCGres predictive values regarding MTX failure-risk were assessed.
Results
The values of hCGres obtained with both methods were highly consistent in the fictive patient and in the actual patient datasets: median relative prediction errors (RPE) were − 0.059 and 9.9 × 10–7, respectively. The ROC AUCs for predictions of MTX failure-risk were 0.90 (95% CI 0.87,0.93) with both NM and the website. The gradual association between increasing hCGres and the 2-year MTX failure-free survival was confirmed.
Conclusion
There is a high consistency of hCGres estimates obtained with the two methods. The website is meant to help clinicians in the interpretation of hCG decline curves of MTX-treated GTN patients. hCGres is now validated for more than 1690 patients in four independent datasets, and its recognition as an early predictor of MTX resistance for treatment adjustment and for the future studies should be considered.
Similar content being viewed by others
Abbreviations
- AUC:
-
Area-under-the-curve
- EMA:
-
European medicines agency
- FDA:
-
Food and drug administration
- FIGO:
-
Federation of gynecology and obstetrics
- GTN:
-
Gestational trophoblastic neoplasia
- hCG:
-
Human chorionic gonadotropin
- hCGres:
-
HCG residual concentration
- MTX:
-
Methotrexate
- NM:
-
NONMEM program®
References
FIGO Oncology Committee (2002) FIGO staging for gestational trophoblastic neoplasia 2000. FIGO oncology committee. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet 77:285–287
Bagshawe KD, Dent J, Newlands ES et al (1989) The role of low-dose methotrexate and folinic acid in gestational trophoblastic tumours (GTT). Br J Obstet Gynaecol 96:795–802
Chalouhi GE, Golfier F, Soignon P et al (2009) Methotrexate for 2000 FIGO low-risk gestational trophoblastic neoplasia patients: efficacy and toxicity. Am J Obstet Gynecol 200:643.e1–6. https://doi.org/10.1016/j.ajog.2009.03.011
Seckl MJ, Sebire NJ, Berkowitz RS (2010) Gestational trophoblastic disease. Lancet Lond Engl 376:717–729. https://doi.org/10.1016/S0140-6736(10)60280-2
You B, Pollet-Villard M, Fronton L et al (2010) Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias. Ann Oncol Off J Eur Soc Med Oncol 21:1643–1650. https://doi.org/10.1093/annonc/mdq033
You B, Harvey R, Henin E et al (2013) Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements. Br J Cancer 108:1810–1816. https://doi.org/10.1038/bjc.2013.123
Osborne RJ, Filiaci V, Schink JC et al (2011) Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. J Clin Oncol 29:825–831. https://doi.org/10.1200/JCO.2010.30.4386
McNeish IA, Strickland S, Holden L et al (2002) Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J Clin Oncol 20:1838–1844. https://doi.org/10.1200/JCO.2002.07.166
Taylor F, Grew T, Everard J et al (1990) (2013) The outcome of patients with low risk gestational trophoblastic neoplasia treated with single agent intramuscular methotrexate and oral folinic acid. Eur J Cancer Oxf Engl 49:3184–3190. https://doi.org/10.1016/j.ejca.2013.06.004
Almufti R, Wilbaux M, Oza A et al (2014) A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment. Ann Oncol Off J Eur Soc Med Oncol 25:41–56. https://doi.org/10.1093/annonc/mdt382
Nelder JA, Mead R (1965) A simplex method for function minimization. Comput J 7:308–313. https://doi.org/10.1093/comjnl/7.4.308
Newlands ES, Mulholland PJ, Holden L et al (2000) Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. J Clin Oncol Off J Am Soc Clin Oncol 18:854–859. https://doi.org/10.1200/JCO.2000.18.4.854
Lurain JR, Nejad B (2005) Secondary chemotherapy for high-risk gestational trophoblastic neoplasia. Gynecol Oncol 97:618–623. https://doi.org/10.1016/j.ygyno.2005.02.004
Wang J, Short D, Sebire NJ et al (2008) Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE). Ann Oncol Off J Eur Soc Med Oncol 19:1578–1583. https://doi.org/10.1093/annonc/mdn181
Alazzam M, Tidy J, Osborne R, et al (2016) Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD008891.pub3. Art. No. CD008891
Essel KG, Bruegl A, Gershenson DM et al (2017) Salvage chemotherapy for gestational trophoblastic neoplasia: utility or futility? Gynecol Oncol 146:74–80. https://doi.org/10.1016/j.ygyno.2017.04.017
Beal SL (2001) Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28:481–504
Ahn JE, Karlsson MO, Dunne A, Ludden TM (2008) Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn 35:401–421. https://doi.org/10.1007/s10928-008-9094-4
Bergstrand M, Karlsson MO (2009) Handling data below the limit of quantification in mixed effect models. AAPS J 11:371–380. https://doi.org/10.1208/s12248-009-9112-5
Beal, S., Sheiner, L.B., Boeckmann, A., & Bauer, R.J., NONMEM User’s Guides. (1989–2009), Icon Development Solutions, Ellicott City, MD, USA, 2009 - Recherche Google. https://www.google.com/search?q=Beal%2C+S.%2C+Sheiner%2C+L.B.%2C+Boeckmann%2C+A.%2C+%26+Bauer%2C+R.J.%2C+NONMEM+User%27s+Guides.+%281989-2009%29%2C+Icon+Development+Solutions%2C+Ellicott+City%2C+MD%2C+USA%2C+2009&ie=utf-8&oe=utf-8&client=firefox-b-ab. Accessed 9 Sep 2018
van Trommel NE, Massuger LF, Schijf CP et al (2006) Early identification of resistance to first-line single-agent methotrexate in patients with persistent trophoblastic disease. J Clin Oncol Off J Am Soc Clin Oncol 24:52–58. https://doi.org/10.1200/JCO.2005.03.3043
Kerkmeijer LG, Thomas CM, Harvey R et al (2009) External validation of serum hCG cutoff levels for prediction of resistance to single-agent chemotherapy in patients with persistent trophoblastic disease. Br J Cancer 100:979–984. https://doi.org/10.1038/sj.bjc.6604849
Savage P, Seckl M, Short D (2008) Practical issues in the management of low-risk gestational trophoblast tumors. J Reprod Med 53:774–780
You B, Fronton L, Boyle H et al (2010) Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor. Urology 76:423–429.e2. https://doi.org/10.1016/j.urology.2010.02.049
Wilbaux M, Hénin E, Oza A et al (2014) Dynamic modeling in ovarian cancer: an original approach linking early changes in modeled longitudinal CA-125 kinetics and survival to help decisions in early drug development. Gynecol Oncol 133:460–466. https://doi.org/10.1016/j.ygyno.2014.04.003
Botteri E, Sandri MT, Bagnardi V et al (2010) Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer. Breast Cancer Res Treat 122:211–217. https://doi.org/10.1007/s10549-009-0668-7
Greiner M, Pfeiffer D, Smith RD (2000) Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. Prev Vet Med 45:23–41
Commissioner O of the Reports - Healthy Innovation, Safer Families: FDA’s 2018 Strategic Policy Roadmap. https://www.fda.gov/aboutfda/reportsmanualsforms/reports/ucm591993.htm. Accessed 7 Oct 2018
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Dekeister, K., Bolze, PA., Tod, M. et al. Validation of an online tool for early prediction of the failure-risk in gestational trophoblastic neoplasia patients treated with methotrexate. Cancer Chemother Pharmacol 86, 15–24 (2020). https://doi.org/10.1007/s00280-020-04086-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-020-04086-0